BioCentury | Sep 21, 2018
Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
BC Extra | Nov 30, 2016
Company News

Arrowhead prunes pipeline over toxicity concerns

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts...
BC Week In Review | Oct 3, 2016
Company News

Arrowhead, Amgen deal

Arrowhead granted Amgen exclusive, worldwide rights to the ARC-LPA cardiovascular program and an exclusive option to license a second RNAi therapy against an undisclosed cardiovascular target. Arrowhead will receive $56.5 million up front, including $35...
BC Extra | Sep 29, 2016
Company News

Amgen, Arrowhead in pair of CV deals

In two deals with Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Amgen Inc. (NASDAQ:AMGN) obtained exclusive, worldwide rights to cardiovascular program ARC-LPA and gained an exclusive option to license a second RNAi therapy against an undisclosed cardiovascular target...
Items per page:
1 - 4 of 4